.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Accenture
Argus Health
Covington
McKesson
US Army
Boehringer Ingelheim
Cantor Fitzgerald
UBS
US Department of Justice

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 200834

« Back to Dashboard
NDA 200834 describes VENLAFAXINE HYDROCHLORIDE, which is a drug marketed by Dr Reddys Labs Ltd, Osmotica Pharm, Sandoz, Pliva Hrvatska Doo, Orchid Hlthcare, Prinston Inc, Sun Pharm Inds Inc, Alembic Pharms Ltd, Aurobindo Pharma Ltd, Yaopharma Co Ltd, Zydus Pharms Usa, Heritage Pharms Inc, Aurobindo Pharma, Teva, Wockhardt, Mylan, Nostrum Labs Inc, Valeant Pharms North, Sun Pharma Global, Zydus Pharms Usa Inc, Anchen Pharms, Macleods Pharms Ltd, Amneal Pharms, and Torrent Pharms Llc, and is included in twenty-seven NDAs. It is available from sixty-nine suppliers. There are two patents protecting this drug. Additional details are available on the VENLAFAXINE HYDROCHLORIDE profile page.

The generic ingredient in VENLAFAXINE HYDROCHLORIDE is venlafaxine hydrochloride. There are seventy-one drug master file entries for this compound. Seventy-five suppliers are listed for this compound. Additional details are available on the venlafaxine hydrochloride profile page.

Summary for 200834

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antidepressants
Formulation / Manufacturing:see details

Pharmacology for NDA: 200834

Suppliers and Packaging for NDA: 200834

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL 200834 ANDA KAISER FOUNDATION HOSPITALS 0179-0161 0179-0161-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0179-0161-01)
VENLAFAXINE HYDROCHLORIDE
venlafaxine hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL 200834 ANDA KAISER FOUNDATION HOSPITALS 0179-0162 0179-0162-01 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (0179-0162-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 37.5MG BASE
Approval Date:Apr 14, 2011TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 75MG BASE
Approval Date:Apr 14, 2011TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 150MG BASE
Approval Date:Apr 14, 2011TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Accenture
Colorcon
Chinese Patent Office
Johnson and Johnson
Medtronic
Fuji
AstraZeneca
Queensland Health
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot